Astria Therapeutics Inc
ATXS12.510USD
+0.080+0.64%
終値 11/07, 16:00（ET）15分遅れの株価
705.99M時価総額
損失額直近12ヶ月PER
詳細情報 Astria Therapeutics Inc 企業名
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Astria Therapeutics Incの企業情報
企業コードATXS
会社名Astria Therapeutics Inc
上場日Jun 25, 2015
最高経営責任者「CEO」Dr. Jill C. Milne, Ph.D.
従業員数78
証券種類Ordinary Share
決算期末Jun 25
本社所在地22 Boston Wharf Road
都市BOSTON
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号02210
電話番号16173491971
ウェブサイトhttps://astriatx.com/
企業コードATXS
上場日Jun 25, 2015
最高経営責任者「CEO」Dr. Jill C. Milne, Ph.D.
Astria Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sun, Oct 26
更新時刻: Sun, Oct 26
株主統計
種類
株主統計
株主統計
比率
Perceptive Advisors LLC
11.49%
Vestal Point Capital, LP
8.01%
Forbion Capital Partners
7.28%
Fidelity Management & Research Company LLC
6.48%
Magnetar Capital Partners LP
5.87%
他の
60.87%
株主統計
株主統計
比率
Perceptive Advisors LLC
11.49%
Vestal Point Capital, LP
8.01%
Forbion Capital Partners
7.28%
Fidelity Management & Research Company LLC
6.48%
Magnetar Capital Partners LP
5.87%
他の
60.87%
種類
株主統計
比率
Investment Advisor
31.18%
Investment Advisor/Hedge Fund
22.93%
Venture Capital
15.69%
Private Equity
11.49%
Hedge Fund
11.30%
Research Firm
4.23%
Individual Investor
0.49%
Pension Fund
0.17%
Bank and Trust
0.09%
他の
2.43%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
263
57.85M
102.50%
-13.18M
2025Q2
263
60.10M
106.50%
-10.94M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Perceptive Advisors LLC
6.49M
11.49%
--
--
Jun 30, 2025
Vestal Point Capital, LP
4.52M
8.01%
+342.00K
+8.18%
Jun 30, 2025
Forbion Capital Partners
4.11M
7.28%
+285.00K
+7.46%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.66M
6.48%
-1.15M
-23.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.18M
5.64%
-222.43K
-6.53%
Jun 30, 2025
Fidelity Institutional Asset Management
2.80M
4.97%
+671.87K
+31.52%
Jun 30, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.52M
4.47%
-116.58K
-4.41%
Jun 30, 2025
VR Adviser, LLC
2.46M
4.35%
--
--
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
ALPS Medical Breakthroughs ETF
0.24%
AltShares Merger Arbitrage ETF
0.09%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
詳細を見る
Virtus LifeSci Biotech Clinical Trials ETF
比率0.94%
ALPS Medical Breakthroughs ETF
比率0.24%
AltShares Merger Arbitrage ETF
比率0.09%
iShares Micro-Cap ETF
比率0.05%
ProShares Ultra Nasdaq Biotechnology
比率0.04%
Invesco Nasdaq Biotechnology ETF
比率0.04%
iShares Biotechnology ETF
比率0.03%
Avantis US Small Cap Equity ETF
比率0.03%
iShares Russell 2000 Value ETF
比率0.02%
iShares Russell 2000 ETF
比率0.01%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
日付
種類
比率
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
